429
Views
12
CrossRef citations to date
0
Altmetric
Clinical Research

11 analytically confirmed cases of mexedrone use among polydrug users

, , , &
Pages 181-186 | Received 05 Aug 2016, Accepted 07 Dec 2016, Published online: 11 Jan 2017

References

  • Advisory Council on the Misuse of Drugs (ACMD). Consideration of the cathinones. London: ACMD; 2010.
  • HMSO. The misuse of drugs (Amendment) (England, Wales and Scotland) Regulations 2010. London: HMSO; 2010.
  • Martínez-Clemente J, Escubedo E, Pubill D, et al. Interaction of mephedrone with dopamine and serotonin targets in rats. Eur Neuropsychopharmacol. 2012;22:231–236.
  • Baumann MH, Ayestas MA Jr, Partilla JS, et al. The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology. 2012;37:1192–1203.
  • Kehr J, Ichinose F, Yoshitake S, et al. Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats. Br J Pharmacol. 2011;164:1949–1958.
  • Ford LT, Berg JD. Analysis of legal high materials by UPLC-MS/TOF as part of a toxicology vigilance system. What are the most popular novel psychoactive substances in the UK? Ann Clin Biochem. 2016;53:640–646.
  • Richeval C, Humbert L, Lazes-Charmetant A, et al. Le stock incroyable d'une consommatrice hors norme de NPS. Toxicol Anal Clin. 2016;28:S28. French.
  • Elliott SP, Brandt SD, Smith C. The first reported fatality associated with the synthetic opioid 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (U-47700) and implications for forensic analysis. Drug Test Anal. 2016;8:875–879.
  • Wood DM, Davies S, Greene SL, et al. Case series of individuals with analytically confirmed acute mephedrone toxicity. Clin Toxicol. 2010;48:924–927.
  • Mackay K, Taylor M, Bajaj N. The adverse consequences of mephedrone use: a case series. Psychiatrist. 2011;35:203–205.
  • Papaseit E, Pérez-Mañá C, Mateus JA, et al. Human pharmacology of mephedrone in comparison with MDMA. Neuropsychopharmacology. 2016;41:2704–2713.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.